$1.17
+0.01 (+0.86%)
Open$1.20
Previous Close$1.16
Day High$1.21
Day Low$1.13
52W High$4.70
52W Low$1.11
Volume—
Avg Volume107.0K
Market Cap10.87M
P/E Ratio—
EPS$-4.59
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+3,428.2% upside
Current
$1.17
$1.17
Target
$41.28
$41.28
$32.58
$41.28 avg
$58.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.64M | 1.62M | 1.37M |
| Net Income | -247,177 | -249,222 | -229,259 |
| Profit Margin | -15.1% | -15.4% | -16.8% |
| EBITDA | -331,691 | -310,875 | -283,649 |
| Free Cash Flow | -127,219 | -197,557 | -123,470 |
| Rev Growth | +20.7% | +12.0% | +3.1% |
| Debt/Equity | 0.09 | 0.11 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |